Table 1.
Baseline clinical characteristics of the participants completing studies 1 and 2
| Study 1 all | Study 1 <3 years diabetes | Study 1 >5 years diabetes | Study 2 | |
|---|---|---|---|---|
| n | 36 | 16 | 20 | 32 |
| Age (years) | 63 ± 6 | 63 ± 6 | 62 ± 6 | 60 ± 6 |
| BMI (kg/m2) | 33 ± 6 | 34 ± 6 | 32 ± 7 | 33 ± 12 |
| Race (% whites) | 89% | 100% | 80% | 85% |
| Sex (% males) | 100% | 100% | 100% | 97% |
| HbA1c (%) | 6.4 ± 0.8 | 6.3 ± 0.5 | 6.5 ± 1.0 | 6.1 ± 0.5 |
| HbA1c (mmol/mol) | 47 ± 9 | 46 ± 6 | 48 ± 11 | 43 ± 5 |
| Duration of diabetes (years) | 5.5 (1–8) | 1 (0.5–2) | 7.5 (6–9.5) | <1 |
| Systolic blood pressure (mmHg) | 128 ± 15 | 127 ± 17 | 128 ± 14 | 125 ± 12 |
| Diastolic blood pressure (mmHg) | 78 ± 9 | 78 ± 9 | 78 ± 9 | 80 ± 8 |
| History of hypertension (%) | 81% | 69% | 90% | 50% |
| Lipid-lowering therapy (%) | 86% | 81% | 90% | 59% |
Data are means ± SD or medians (25th–75th percentile).